Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors

Sponsor
Gustave Roussy, Cancer Campus, Grand Paris
Study ID
NCT03982173
Phase
PHASE2
Status
Withdrawn

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To determine the efficacy (as measured by overall tumour response rate) of the combination of durvalumab and tremelimumab when given to previously treated patients with solid tumors harboring a high mutational load.

Key Dates

Start date
Sep 30, 2020
Status verified
Jan 2023
Primary completion
Sep 30, 2024
Completion
Dec 5, 2024

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: previously treated patients with solid tumors
    previously treated patients with solid tumors harboring a high mutational load.

Primary Outcome Measure

Objective tumour response rate [ Time Frame: at 12 weeks ]

Related Studies